MRC Cancer Unit, University of Cambridge, Cambridge Biomedical Campus, Box 197, Cambridge CB2 0XZ, United Kingdom; Department of Gastroenterology, Addenbrookes Hospital, Cambridge University NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, United Kingdom; Department of Gastroenterology, Hinchingbrooke Hospital, North West Anglia Foundation Trust, Huntingdon, PE29 6NT, United Kingdom.
University Hospitals, Cleveland Medical Center, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Gastrointest Endosc Clin N Am. 2021 Jan;31(1):43-58. doi: 10.1016/j.giec.2020.08.004.
The rapid increase in the incidence of esophageal adenocarcinoma in Western populations over the past 4 decades and its associated poor prognosis, unless detected early has generated great interest in screening for the precursor lesion Barrett's esophagus (BE). Recently, there have been significant developments in imaging-based modalities and esophageal cell-sampling devices coupled with biomarker assays. In this review, the authors discuss the rationale for screening for BE and the factors to consider for targeting the at-risk population. They also explore future avenues for research in this area.
在过去的 40 年中，西方人群中食管腺癌的发病率迅速上升，且其预后较差，除非早期发现，因此人们对筛查癌前病变 Barrett 食管（BE）产生了浓厚的兴趣。最近，基于影像学的方法和食管细胞采样设备以及生物标志物检测都取得了重大进展。在这篇综述中，作者讨论了筛查 BE 的基本原理和针对高危人群的考虑因素。他们还探讨了该领域未来的研究方向。
